Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Reviews in Endocrine and Metabolic Disorders is Scopus-indexed (Q1, CiteScore 19.2), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer.
Checked against the index lists dated .
ISSN 1389-9155Verify ISSN ↗1573-2606Verify ISSN ↗
Publisher: Springer
Cost to publish: About US$5,590 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Endocrinology, Diabetes and Metabolism | 12 / 250 | 95th | Q1 |
| Endocrinology | 7 / 132 | 95th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2000–present, best quartile Q1, CiteScore 19.2.
Reviews in Endocrine and Metabolic Disorders is Q1 in Endocrinology, Diabetes and Metabolism (rank 12 of 250) and Q1 in Endocrinology (rank 7 of 132), by CiteScore 2025.
Reviews in Endocrine and Metabolic Disorders is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 19.2, which places it in quartile Q1 at the 95th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.834, quartile Q1, with an H-index of 113.
The publisher lists an article processing charge of about US$5,590 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Reviews in Endocrine and Metabolic Disorders is published by Springer. Its print ISSN is 1389-9155 and its online ISSN is 1573-2606.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Reviews in Endocrine and Metabolic Disorders has an h-index of 129 and a 2-year mean of 6.3 citations per paper (OpenAlex). Its Scopus CiteScore is 19.2, quartile Q1. On 2-year citations it ranks #21 of 246 Scopus journals in Endocrinology, Diabetes and Metabolism.
Reviews in Endocrine and Metabolic Disorders published 72 papers in 2025; its busiest recent year was 2023 with 89. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2025–2026), authors are most often from Spain (14.5%), Italy (12.9%) and Germany (11.8%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.